Ripple Therapeutics Announces First Patient Treated in Phase II Trial Evaluating IBE-814 IVT in DME and RVO

Ontario Industry Updates
Written By Viktoriya Shabat
ripple-logo.png

Ripple Therapeutics Corporation, a clinical stage, ophthalmology-focused developer of novel pharmaceuticals, announced, on April 20, that the first patient has been treated in RIPPLE-1, a Phase II trial evaluating IBE-814 IVT, a proprietary intravitreal dexamethasone implant targeting inflammatory retinal diseases.

Viktoriya Shabat
Previous

Canada-Israel Cardiovascular Innovation Forum Announced Selected Applications
Next

OBIO Announces Launch of OBIO CAAP® for 2021